AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
bevantolol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| beta-adrenoreceptor antagonists | 360 | 59170-23-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.30 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.18 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 8 % | Benet LZ, Broccatelli F, Oprea TI |
| BA (Bioavailability) | 57 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.67 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 5.50 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.02 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.90 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 1.699 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 3.491 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 12.106 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 29.309 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 17.410 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 22.420 | % | High | 1 |
| herg | hERG pIC50 | 5.471 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 19.999 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 46.989 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 16.220 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AKT1,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK12,MAPK7,MAPK9,MET,MTOR,NTRK2,PAK4,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 | 49 | |||
| kinase-selectivity-class | AKT3,AXL,BRAF,CDK9,DDR1,EIF2AK3,EPHB4,ERBB2,GRK2,MAPK7,PDK4,PIK3CD,PRKCD,SIK2,SIK3,STK33,TEK,TTK | 18 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 2.427 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 93.972 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 16.570 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 7.063 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 35.830 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 229.615 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 54.880 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 19.780 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 814.704 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1987 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C07AB06 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Beta blocking agents, selective |
| ATC | C07BB06 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS AND THIAZIDES Beta blocking agents, selective, and thiazides |
| MeSH PA | D000319 | Adrenergic beta-Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D018674 | Adrenergic Antagonists |
| MeSH PA | D058671 | Adrenergic beta-1 Receptor Antagonists |
| CHEBI has role | CHEBI:35530 | β-adrenergic antagonist |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
| CHEBI has role | CHEBI:38070 | anti-arrhythmia drug |
| CHEBI has role | CHEBI:38215 | calcium channel blocker |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
Related Drugs by ATC class:
C07AB Beta blocking agents, selective 13 drugs
C07BB Beta blocking agents, selective, and thiazides 5 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.28 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Beta-1 adrenergic receptor | GPCR | ANTAGONIST | WOMBAT-PK | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| D01369 | KEGG_DRUG |
| C0053532 | UMLSCUI |
| CHEBI:238698 | CHEBI |
| CHEMBL314010 | ChEMBL_ID |
| CHEMBL2106060 | ChEMBL_ID |
| DB01295 | DRUGBANK_ID |
| C021148 | MESH_SUPPLEMENTAL_RECORD_UI |
| 2372 | PUBCHEM_CID |
| 4115 | INN_ID |
| 42864-78-8 | SECONDARY_CAS_RN |
| 34ZXW6ZV21 | UNII |
| 008146 | NDDF |
| 008147 | NDDF |
Pharmaceutical products:
None